|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7 Pt 1
|
|
pubmed:dateCreated |
2006-4-12
|
|
pubmed:abstractText |
The tolerability of molecularly targeted agents in older patients has not been specifically examined. Adverse event data from clinical trials in the Princess Margaret Hospital Phase II Consortium database were analyzed to address this question.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2141-9
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:16609027-Adult,
pubmed-meshheading:16609027-Age Factors,
pubmed-meshheading:16609027-Aged,
pubmed-meshheading:16609027-Aged, 80 and over,
pubmed-meshheading:16609027-Antineoplastic Agents,
pubmed-meshheading:16609027-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16609027-Clinical Trials, Phase II as Topic,
pubmed-meshheading:16609027-Databases as Topic,
pubmed-meshheading:16609027-Drug Delivery Systems,
pubmed-meshheading:16609027-Drug Toxicity,
pubmed-meshheading:16609027-Humans,
pubmed-meshheading:16609027-Middle Aged,
pubmed-meshheading:16609027-Neoplasms,
pubmed-meshheading:16609027-Ontario,
pubmed-meshheading:16609027-Outcome Assessment (Health Care)
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination.
|
|
pubmed:affiliation |
Princess Margaret Hospital Phase II Consortium, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, N.I.H., Extramural
|
